Marinus Pharmaceuticals (MRNS) News Today $1.66 +0.06 (+3.75%) (As of 09/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst DaySeptember 20 at 8:00 AM | businesswire.comMarinus Pharmaceuticals to Outline Strategic Vision at Investor & Analyst DaySeptember 19 at 1:45 AM | msn.comMarinus Pharmaceuticals to Present at 2024 Cantor Global Healthcare ConferenceSeptember 18 at 8:29 AM | msn.comMarinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Upgraded by StockNews.comSeptember 18 at 2:45 AM | americanbankingnews.comMarinus Pharmaceuticals (NASDAQ:MRNS) Lifted to Hold at StockNews.comStockNews.com raised shares of Marinus Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday.September 18 at 2:44 AM | marketbeat.comMarinus Pharmaceuticals' (MRNS) Overweight Rating Reiterated at Cantor FitzgeraldSeptember 17 at 5:25 AM | americanbankingnews.com695,972 Shares in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Purchased by Acadian Asset Management LLCAcadian Asset Management LLC purchased a new position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 695,972 shares of the biopharmaceutical company's stock, valued at approximatelSeptember 17 at 3:48 AM | marketbeat.comTruist Financial Reaffirms Their Buy Rating on Marinus (MRNS)September 16, 2024 | markets.businessinsider.comMarinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and set a $13.00 price objective on shares of Marinus Pharmaceuticals in a research report on Monday.September 16, 2024 | marketbeat.comMarinus Pharmaceuticals (NASDAQ:MRNS) Given Overweight Rating at Cantor FitzgeraldSeptember 11, 2024 | americanbankingnews.comStockNews.com Upgrades Marinus Pharmaceuticals (NASDAQ:MRNS) to HoldSeptember 11, 2024 | americanbankingnews.comMarinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare ConferenceSeptember 10, 2024 | finance.yahoo.comCantor Fitzgerald Reaffirms "Overweight" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 target price on shares of Marinus Pharmaceuticals in a report on Monday.September 9, 2024 | marketbeat.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Rating of "Hold" by BrokeragesMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Get Free Report) has earned a consensus rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and three have given a buy rating to tSeptember 5, 2024 | marketbeat.comMarinus Pharmaceuticals Hosts Investor and Analyst DayAugust 27, 2024 | msn.comMarinus Pharmaceuticals (NASDAQ:MRNS) Downgraded by StockNews.com to "Sell"StockNews.com cut Marinus Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday.August 22, 2024 | marketbeat.comMarinus Pharmaceuticals Reports Robust Q2 2024 Financial Results and Business ProgressAugust 21, 2024 | msn.comFY2024 EPS Estimates for Marinus Pharmaceuticals, Inc. Increased by Cantor Fitzgerald (NASDAQ:MRNS)Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2024 EPS estimates for Marinus Pharmaceuticals in a research note issued to investors on Wednesday, August 14th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmacAugust 19, 2024 | marketbeat.comBuy Rating Affirmed for Marinus Pharmaceuticals on Strong Ztalmy Sales and Promising Pipeline DevelopmentsAugust 16, 2024 | markets.businessinsider.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportAugust 16, 2024 | finance.yahoo.comMarinus Pharmaceuticals, Inc. Expected to Post Q3 2024 Earnings of ($0.47) Per Share (NASDAQ:MRNS)Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2024 earnings per share (EPS) estimates for Marinus Pharmaceuticals in a report released on Wednesday, August 14th. HC Wainwright analyst D. Tsao now anticipates that the biopharmacAugust 16, 2024 | marketbeat.comMarinus Pharmaceuticals IncAugust 15, 2024 | money.usnews.comMaintaining Hold on Marinus Pharmaceuticals Amid Financial Uncertainty and Pipeline PotentialAugust 15, 2024 | markets.businessinsider.comLadenburg Thalmann Downgrades Marinus Pharmaceuticals (MRNS)August 15, 2024 | msn.comMarinus Pharmaceuticals, Inc. Forecasted to Earn FY2028 Earnings of $2.72 Per Share (NASDAQ:MRNS)Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) - Equities research analysts at HC Wainwright cut their FY2028 EPS estimates for Marinus Pharmaceuticals in a note issued to investors on Wednesday, August 14th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical companyAugust 15, 2024 | marketbeat.comMarinus Pharmaceuticals (NASDAQ:MRNS) Raised to "Hold" at StockNews.comStockNews.com raised Marinus Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday.August 14, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)HC Wainwright restated a "buy" rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a research report on Wednesday.August 14, 2024 | marketbeat.comMarinus Pharmaceuticals earnings preview: what Wall Street is expectingAugust 14, 2024 | markets.businessinsider.comMarinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial ResultsAugust 14, 2024 | finance.yahoo.comBuy Rating Affirmed for Marinus Pharmaceuticals on Strong ZTALMY Performance and Promising Pipeline OutlookAugust 13, 2024 | markets.businessinsider.comPacific Defense Announces US Army CMFF Program TeamAugust 13, 2024 | businesswire.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Recommendation of "Moderate Buy" by AnalystsMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have given a buyAugust 11, 2024 | marketbeat.comInsider Selling: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) CEO Sells 12,145 Shares of StockAugust 8, 2024 | insidertrades.comInvestors Are Invited To Participate In The Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law FirmAugust 7, 2024 | stockhouse.comMarinus Pharmaceuticals to Announce Q2 Financial ResultsAugust 6, 2024 | msn.comMarinus Pharmaceuticals (MRNS) Set to Announce Earnings on TuesdayMarinus Pharmaceuticals (NASDAQ:MRNS) will be releasing earnings before the market opens on Tuesday, August 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=614811)August 6, 2024 | marketbeat.com3 Biotech Stocks to Sell in August Before They Crash & BurnAugust 6, 2024 | investorplace.comAugust 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against MRNSAugust 5, 2024 | globenewswire.comMarinus Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNSAugust 5, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNSAugust 3, 2024 | globenewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit Filed by Rosen Law FirmAugust 3, 2024 | prnewswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)August 2, 2024 | tmcnet.comMRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law FirmAugust 2, 2024 | tmcnet.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MarinusAugust 2, 2024 | globenewswire.comLevi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNSAugust 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNSAugust 1, 2024 | prnewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law FirmAugust 1, 2024 | prnewswire.comThe past three years for Marinus Pharmaceuticals (NASDAQ:MRNS) investors has not been profitableAugust 1, 2024 | finance.yahoo.comShareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) Urged to Join Class Action – Contact Levi & Korsinsky to Learn MoreJuly 31, 2024 | globenewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MarinusJuly 31, 2024 | prnewswire.com Get Marinus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget Trump and Kamala (Ad)Forget Trump and Kamala. I don't care who you vote for - This calendar is the only thing that matters right now. Download my Dividend Calendar here MRNS Media Mentions By Week MRNS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRNS News Sentiment▼0.250.49▲Average Medical News Sentiment MRNS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRNS Articles This Week▼105▲MRNS Articles Average Week Get Marinus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RAPT Therapeutics News Today Puma Biotechnology News Today Atea Pharmaceuticals News Today Editas Medicine News Today Corvus Pharmaceuticals News Today Lexeo Therapeutics News Today biote News Today Aurora Cannabis News Today Lyell Immunopharma News Today AC Immune News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRNS) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marinus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
